financetom
Business
financetom
/
Business
/
Nvidia takes EU antitrust regulators to court for probing AI startup Run:ai bid
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nvidia takes EU antitrust regulators to court for probing AI startup Run:ai bid
Feb 24, 2025 9:32 AM

BRUSSELS, Feb 24 (Reuters) - U.S. chipmaker Nvidia ( NVDA )

has sued EU antitrust regulators for accepting an

Italian request last year to scrutinise its acquisition of AI

startup Run:ai, saying they had flouted an earlier court ruling

restricting their merger powers on minor deals.

While the case does not have any impact on the Run:ai deal

which was eventually approved by the EU competition watchdog in

December last year, a ruling favouring Nvidia ( NVDA ) may further curb

the regulator's merger power.

Businesses have been concerned in recent years with the

European Commission flexing a rarely-used power called Article

22 to assess small deals even though these are below the EU's

merger revenue threshold.

The EU executive says it is concerned about killer

acquisitions in which big companies buy startups to shut them

down, but companies criticise such moves as regulatory

over-reach.

Europe's highest court, however, in a landmark ruling in

September last year said the Commission cannot encourage or

accept referrals of deals without a European dimension from

national enforcers when the latter do not have the powers to

examine such deals under their own national laws.

Nvidia ( NVDA ) cited the ruling in its lawsuit filed with the

Luxembourg-based General Court, Europe's second-highest,

according to a filing on the court website.

"The decision unlawfully accepted a referral request from

the Italian Autorità Garante della Concorrenza (AGCM), regarding

a transaction that fell below the EU Merger Regulation and

member state merger control thresholds, based on the AGCM's

exercise of loosely defined, ex post, discretionary call-in

powers," Nvidia ( NVDA ) said.

It said regulators' decision to take up the Italian request

breaches principles of institutional balance, legal certainty,

proportionality and equal treatment.

The case is T-15/25 Nvidia ( NVDA ) v Commission.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Boehringer Ingelheim wins trial in two Zantac lawsuits
Boehringer Ingelheim wins trial in two Zantac lawsuits
Feb 25, 2025
Feb 25 (Reuters) - Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries. A state court jury in Chicago on Monday found in favor of the privately held German drugmaker following a joint trial of individual cases brought by Chicago residents...
Colabor Group Posts Higher Profit, Revenue for Fiscal Fourth Quarter
Colabor Group Posts Higher Profit, Revenue for Fiscal Fourth Quarter
Feb 25, 2025
05:28 PM EST, 02/25/2025 (MT Newswires) -- Colabor Group ( COLFF ) , after trade Tuesday, reported higher net earnings and revenue for its fiscal fourth quarter. The food-distribution company said earnings from continuing operations were $548,000 or $0.01 per share, in the quarter Dec. 28, up from $354,000, in the year-prior period. This increase was mainly due to a...
AMC tops revenue target as box office hits drive strong demand
AMC tops revenue target as box office hits drive strong demand
Feb 25, 2025
Feb 25 (Reuters) - AMC Entertainment ( AMC ) topped Wall Street estimates for quarterly revenue on Tuesday, boosted by wildly popular releases including Moana 2 and Wicked that helped draw a strong crowd of moviegoers. Shares of the company rose about 3% in extended trading after it reported a 20% jump in attendance in theaters in the fourth quarter....
Vaxcyte 2024 Loss Narrows
Vaxcyte 2024 Loss Narrows
Feb 25, 2025
05:20 PM EST, 02/25/2025 (MT Newswires) -- Vaxcyte ( PCVX ) reported a full-year 2024 net loss late Tuesday of $3.80 per diluted share, narrower than a per-share loss of $4.14 a year earlier. Analysts polled by FactSet expected a per-share loss of $3.91. The company said it had cash, cash equivalents and investments of $3.13 billion as of Dec....
Copyright 2023-2026 - www.financetom.com All Rights Reserved